drugset / Trial / NCT03618043
Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label study of SH-1028 with dose escalation cohorts in locally advanced solid cancer patients who have progressed following prior therapy with an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKI) agent or standard treatment.
Timeline
- Start
- 2018-09-13
- Primary completion
- 2019-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORITINIB | Small molecule | 60 mg | Oral |
| Subject | ORITINIB | Small molecule | 120 mg | Oral |
| Subject | ORITINIB | Small molecule | 180 mg | Oral |
| Subject | ORITINIB | Small molecule | 240 mg | Oral |
| Subject | ORITINIB | Small molecule | 320 mg | Oral |